|
Getting your Trinity Audio player ready...
|
Datavault AI Inc. (NASDAQ: DVLT) has entered into a groundbreaking agreement with Scilex Holding Company (NASDAQ: SCLX), granting Scilex a worldwide exclusive license—with rights to sublicense—its proprietary AI-driven data tokenization technology for the biotech and biopharma industries.
This agreement marks a defining moment for Datavault AI (DVLT), whose patented “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623) establishes a secure framework for converting sensitive genomic and therapeutic data into tradable digital assets. The technology underpins the creation of a Biotech Exchange Platform, enabling tokenization, trading, and monetization of genomic, diagnostic, and pharmaceutical intellectual property—paving the way for a new financial layer within the life sciences sector.
Breaking News Bonus: Watch these Undervalued Companies with major news today: Roadzen Inc. (NASDAQ: RDZN), Power Metallic Mines Inc. (OTCQB: PNPNF | TSXV: PNPN), Datavault AI Inc. (Nasdaq: DVLT), Peraso Inc (NASDAQ: PRSO), Kartoon Studios, Inc (NASDAQ: TOON), Specificity Inc. (OTCID: SPTY), Intelligent Bio Solutions Inc. (NASDAQ: INBS) and Scilex Holding Company (NASDAQ: SCLX) are moving actively in pre-market and early trading sessions. Also stay alert as this is short squeeze season and our scanners indicate “shorting” in ALL of these stocks previous from today.
Scilex Holding Company (SCLX), a revenue-generating innovator in non-opioid pain management and emerging therapeutic solutions, will integrate DVLT’s platform to launch a next-generation data marketplace. The platform aims to unlock an estimated $2 trillion opportunity across global pharmaceutical and diagnostic sales through the tokenization of real-world biotech assets (RWAs).
Beyond data security, the collaboration opens the door for non-dilutive funding mechanisms—allowing biotech and pharma companies to raise capital by tokenizing intellectual property, research data, and therapeutic innovations.
This exclusive license positions Datavault AI (DVLT) at the forefront of AI-driven tokenization and biotech finance, bridging the gap between digital assets and life science commercialization—potentially reshaping how genomic and pharmaceutical data are valued, traded, and monetized worldwide.